Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents
Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · May 10, 2002
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
Bipolar disorder (BPD) in children and adolescents is a serious illness that carries a high risk for chronicity, impairing comorbidities, and completed suicide. Treatment options are often limited by inefficacy or intolerable side effects. Open trials in adult bipolar subjects and several case series in children and adolescents provide preliminary evidence that clozapine, an atypical antipsychotic, may be effective in treatment-resistant bipolar disorder. The first specific aim of this study is to test the efficacy and safety of clozapine compared to placebo in a double-blind study of child...
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA (All 5 must be met): Children with BPD
- • Ages 8-17
- • Currently meets criteria for bipolar disorder, manic or mixed, as determined by the K-SADS diagnostic interview.
- • Treatment-resistant, defined as a history of unsuccessful trials of lithium (documented level of greater than 0.8 mEq/L), valproic acid (documented level of greater than 50 ug/ml), carbamazepine (documented level greater than or equal to 6 ug/ml), a neuroleptic as well as a combination of two of these agents. Each trial must have been at least 6 weeks long. A trial will be considered unsuccessful if the medication was discontinued because of intolerable side-effects.
- • The child should be in treatment with a community psychiatrist to whom they will return upon completion of the study.
- • Current CGAS score less than 50
- • EXCLUSION CRITERIA: Children with BPD
- • Full scale IQ less than 80
- • Meets criteria for substance use disorder in the three months prior to randomization
- • Currently pregnant, lactating, or sexually active without using a barrier method of contraception
- • Previous treatment with clozapine
- • History of seizures
- • History of leukopenia or agranulocytosis
- • Presence of an unstable medical illness
- • INCLUSION CRITERIA: CONTROLS
- • Control subjects will be age- and sex- matched to the BPD subjects. They will have normal physical and neurological examinations, and an identified primary care physician. Both control subjects and their first-degree relatives must be free of current or past psychopathology.
- • EXCLUSION CRITERIA: CONTROLS
- • I.Q less than 80; ongoing medical illness; neurologic disorder (including seizures); pregnancy; meeting past or present criteria for any diagnosis on the K-SADS-PL; meeting criterion A of post-traumatic stress disorder (exposure to a traumatic event).
About National Institute Of Mental Health (Nimh)
The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials